Abstract
One of the main approaches to the treatment of cardiovascular diseases is to block pathways and enzymes within the Renin-Angiotensin System (RAS) involved in the modulation of Angiotensin II. Besides this complex system, many other alternative strategies may represent interesting targets for new and more effective cardiovascular therapies. Many different approaches have led medicinal chemists to develop new molecules with the aim of improving current antihypertensive therapies. The development of these new compounds is based on different strategies which include the synthesis of new hybrid compounds in which two or more pharmacophore groups are combined together to give a new entity with better pharmacodynamic properties and fewer side effects, and the development of new molecules with targets such as renin, angiotensin (1-7) and urotensin-II. The aim of this review is to present various approaches used to improve antihypertensive therapy, developing both original molecules with new mechanisms of action (such as renin inhibitors, or Mas-agonists) and new hybrid cardiovascular drugs targeting multiple factors involved in hypertensive disease (NO-ACE inhibitors, NO-sartans, AT1/ETA antagonists).
Keywords: Hypertension, multi-target drug, ACE, ECE, NEP, nitric oxide releasing drug, Mas receptor, ETa receptor, AT1 receptor, urotensin-II
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: New Emerging Prospects in the Pharmacotherapy of Hypertension
Volume: 6 Issue: 1
Author(s): A. Balsamo, V. Calderone and S. Rapposelli
Affiliation:
Keywords: Hypertension, multi-target drug, ACE, ECE, NEP, nitric oxide releasing drug, Mas receptor, ETa receptor, AT1 receptor, urotensin-II
Abstract: One of the main approaches to the treatment of cardiovascular diseases is to block pathways and enzymes within the Renin-Angiotensin System (RAS) involved in the modulation of Angiotensin II. Besides this complex system, many other alternative strategies may represent interesting targets for new and more effective cardiovascular therapies. Many different approaches have led medicinal chemists to develop new molecules with the aim of improving current antihypertensive therapies. The development of these new compounds is based on different strategies which include the synthesis of new hybrid compounds in which two or more pharmacophore groups are combined together to give a new entity with better pharmacodynamic properties and fewer side effects, and the development of new molecules with targets such as renin, angiotensin (1-7) and urotensin-II. The aim of this review is to present various approaches used to improve antihypertensive therapy, developing both original molecules with new mechanisms of action (such as renin inhibitors, or Mas-agonists) and new hybrid cardiovascular drugs targeting multiple factors involved in hypertensive disease (NO-ACE inhibitors, NO-sartans, AT1/ETA antagonists).
Export Options
About this article
Cite this article as:
Balsamo A., Calderone V. and Rapposelli S., New Emerging Prospects in the Pharmacotherapy of Hypertension, Cardiovascular & Hematological Agents in Medicinal Chemistry 2008; 6 (1) . https://dx.doi.org/10.2174/187152508783329993
DOI https://dx.doi.org/10.2174/187152508783329993 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular Pathology from Smoking: Look at the Microcirculation!
Current Vascular Pharmacology Anti-IL-1 β Therapies
Recent Patents on DNA & Gene Sequences Attention Deficit Hyperactive Disorder and Occurrence of Tic Disorders in Children and Adolescents—What is the Verdict
Current Pediatric Reviews Anti-atherosclerotic Effects of Spice-Derived Phytochemicals
Current Medicinal Chemistry Mitral Balloon Valvuloplasty: State-of-the-Art Paper
Current Cardiology Reviews The Effect of Stevia on the Chicken Embryo Heart
Cardiovascular & Hematological Disorders-Drug Targets The Transcriptome in Blood: Challenges and Solutions for Robust Expression Profiling
Current Molecular Medicine Clopidogrel, Aspirin and Proton Pump Inhibition after Percutaneous Valve Implants: An Update
Current Pharmaceutical Design Pharmacokinetic Interaction Between Verapamil and Methylxanthine Derivatives in Mice
Drug Metabolism Letters Persistent Pulmonary Hypertension of the Newborn: Therapeutical Approach
Mini-Reviews in Medicinal Chemistry Soy Isoflavones and Exercise: Possible Benefits for Postmenopausal Womens Cardiovascular Health
Current Women`s Health Reviews Examination of QTc Values in Critically Ill Patients Diagnosed with Delirium and Prescribed Atypical Antipsychotics
Current Drug Safety Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology Trends in the Treatment of Hepatocellular Carcinoma
Current Drug Therapy Increased Radioisotope Accumulation Around Pulmonary Arteriovenous Fistula Illustrated by Tc-99m-macroaggregated Albumin Scintigraphy and SPECT/CT in a Patient with Osler-Weber-Rendu Syndrome
Current Medical Imaging Comprehensive in silico Study of GLUT10: Prediction of Possible Substrate Binding Sites and Interacting Molecules
Current Pharmaceutical Biotechnology Migraine and Coronary Artery Disease: An Open Study on the Genetic Polymorphism of the 5, 10 Methylenetetrahydrofolate (MTHFR) and Angiotensin I-Converting Enzyme (ACE) Genes
Central Nervous System Agents in Medicinal Chemistry Bacterial Conjunctivitis in Childhood: Etiology, Clinical Manifestations, Diagnosis, and Management
Recent Patents on Inflammation & Allergy Drug Discovery Multiple Lipid-lowering Treatment in Pediatric Patients with Hyperlipidemia
Medicinal Chemistry Sex Differences in Oxidative Stress Biomarkers
Current Drug Targets